Zanubrutinib vs Bendamustine + Rituximab (BR) in Patients With Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Extended Follow-Up of the SEQUOIA Study

Stephen Opat,¹ Talha Munir,² Mazyar Shadman,³ Tadeusz Robak,⁴ Jennifer R. Brown,⁵ Brad S. Kahl,⁶ Paolo Ghia,ⁿ Krzysztof Giannopoulos,ⁿ Martin Šimkovič,¹⁰ Anders Österborg,¹¹ Luca Laurenti,¹² Patricia Walker,¹³ Hanna Ciepluch,¹⁴ Richard Greil,^{15,16} Merit Hanna,¹⁷ Monica Tani,¹⁸ Marek Trněný,¹⁹ Danielle M. Brander,²⁰ Ian W. Flinn,²¹ Sebastian Grosicki,²² Emma Verner,^{23,24} Alessandra Tedeschi,²⁵ Sophie De Guibert,²⁶ Gayane Tumyan,²⁷ Kamel Laribi,²⁸ José Antonio García,²⁹ Jian-Yong Li,³⁰ Tian Tian,³¹ Vanitha Ramakrishnan,³¹ Yu Liu,³¹ Andy Szeto,³¹ Jason Paik,³¹ Aileen Cohen,³¹ Constantine S. Tam,^{32*} Wojciech Jurczak^{33*}

¹Monash Health and Clinical Haematology Unit, Monash University, Clayton, VIC, Australia; ²Haematology, Haematology, Haematology, Haematology, Haematology, Haematology, Leeds, UK; ³Fred Hutchinson Cancer Center, University of Washington, Seattle, WA, USA; ⁴Medical University of Lodz, Lodz, Poland; Dana-Farber Cancer Institute, Boston, MA, USA; Washington University School of Medicine, St Louis, MO, USA; Strategic Research Program on Chronic Lymphocytic Leukemia, Division of Experimental Oncology, IRCCS Ospedale San Raffaele and Università Vita-Salute San Raffaele, Milan, Italy; 8Experimental Hematooncology Department, Medical University of Lublin, Poland; 9Hematology Department, St John's Cancer Centre, Lublin, Poland; 10University Hospital Hradec Králové, Hradec Králové, Czech Republic; 11Department of Hematology, Karolinska University Hospital Solna, Stockholm, Sweden; 12 Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; 13 Peninsula Private Hospital, Frankston, Melbourne, VIC, Australia; 14 Department of Hematology, Copernicus Regional Oncology Centre, Gdansk, Poland; 15 Third Medical Department With Hematology, Medical Oncology, Rheumatology and Infectiology, Paracelsus Medical University, Salzburg, Austria; ¹⁶Salzburg, Austria; Cancer Research Institute Center for Clinical Cancer and Immunology Trials, Salzburg, Austria; Cancer Cluster Salzburg, Salzburg, Austria; ¹⁷Department of Haematology, Waitemata District Health Board, Takapuna, New Zealand; ¹⁸Hematology Unit, Santa Maria delle Croci Hospital, Ravenna, Italy; ¹⁹First Department of Medicine, First Faculty of Medicine, Charles University, General Hospital, Prague, Czech Republic; ²⁰Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, NC, USA; ²¹Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA; ²²Department of Hematology and Cancer Prevention, School of Public Health, Medical University of Silesia, Katowice, Poland; ²³Concord Repatriation General Hospital, Concord, NSW, Australia; ²⁴University of Sydney, Sydney, NSW, Australia; ²⁵Department of Hematology, Azienda Socio Sanitaria Territoriali Grande Ospedale Metropolitano Niguarda, Milan, Italy; ²⁶Hôpital Pontchaillou, Rennes, France; ²⁷Department of Chemotherapy of Hemoblastosis, Blokhin Russian Cancer Research Center, Moscow, Russia; ²⁸Hematology Department, Centre Hospitalier du Mans, Le Mans, France; ²⁹Laboratorio de Flujo, Servicio de Hematología y Hemoterapia, Hospital Universitario de Getafe, Getafe, Madrid, Spain; ³⁰Department of Hematology, Jiangsu Province Hospital, Nanjing, China; 31BeiGene USA, San Mateo, CA, USA; 32Alfred Health and Monash University, Melbourne, VIC, Australia; 33Maria Skłodowska-Curie National Research Institute of Oncology, Krakow, Poland

BACKGROUND


*Co-senior authors

- BTK inhibitors have transformed the therapeutic landscape for CLL/SLL by demonstrating prolonged PFS and OS over chemoimmunotherapy, the traditional standard of care¹
- Zanubrutinib, a next-generation BTK inhibitor designed to minimize off-target binding and limit associated side effects,² is approved in the US,³ EU,⁴ and China⁵ for CLL/SLL
- Results from the SEQUOIA study (NCT03336333), at a median follow-up of 26.2 months, demonstrated superior PFS in treatment-naive patients with CLL/SLL without del(17p) who received zanubrutinib vs BR (HR, 0.42; 95% CI, 0.28-0.63; 2-sided P < .0001); results were similar in treatment-naive patients with del(17p) who received zanubrutinib monotherapy⁶
- An independent data monitoring committee determined that the SEQUOIA study met its primary endpoint at the interim analysis⁶
- Here, we report the updated efficacy and safety results from the SEQUOIA study after approximately 18 months of additional follow-up (data cutoff: 31 October 2022)

METHODS

• Methodological details have been published⁶ and are summarized in Figure 1

Figure 1. Study Design



C, cycle; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; CRi, CR with incomplete hematologic recovery; FCR, fludarabine, cyclophosphamide, rituximab; FISH, fluorescence in situ hybridization; IGHV, immunoglobulin heavy variable; INV, investigator; iwCLL, International Workshop on Chronic Lymphocytic Defined as Cumulative Illness Rating Scale >6, creatinine clearance < 70 mL/min, or a history of previous severe infection or multiple infections within the last 2 years; b One patient without del(17p) was misassigned to the nonrandomly assigned cohort of patients with del(17p). The patient is excluded from the efficacy analysis in this cohort; ^c Defined as the time from randomization to death or the date of progression on the next line of therapy subsequent to study treatment

RESULTS

Patients

- As of 31 October 2022, 479 patients without del(17p) had been randomized to receive zanubrutinib (n=241) or BR (n=238), and 111 patients with del(17p) received zanubrutinib monotherapy; 180 patients (74.7%) without del(17p) and 78 patients (70.3%) with del(17p) were still receiving zanubrutinib
- The median follow-up was 43.7 months (range, 0-60.0 months) in cohort 1 and 47.9 months (range, 5.0-56.9 months) in cohort 2
- In arm B, 188 patients (79.0%) completed their BR regimen, 86 (36.1%) had progression irrespective of completing the full 6 cycles, and 41 (17.2%) crossed over to receive zanubrutinib after centrally confirmed disease progression
- and 29.7%, respectively

• Zanubrutinib discontinuation rates in patients without and with del(17p) were 24.9%

• Baseline demographics and disease characteristics were similar across treatment

Table 1 Patient Characteristics and Paceline Demographics


		Patients without del(17p)		
	Arm A: zanubrutinib (n=241)	Arm B: BR (n=238)	Arm C: zanubrutinib (n=111)ª	
Age, median (range), years	70 (40-86)	70 (35-87)	71 (42-87)	
Age ≥65 years, n (%) ^b	198 (82)	195 (82)	95 (86)	
Male, n (%)	154 (64)	144 (61)	79 (71)	
ECOG PS 2, n (%)	15 (6)	20 (8)	14 (13)	
Geographic region, n (%)				
North America	34 (14)	28 (12)	12 (11)	
Europe	174 (72)	172 (72)	52 (47)	
Asia-Pacific	33 (14)	38 (16)	47 (42)	
Binet stage C, n (%) ^c	70 (29)	70 (29)	39 (35)	
Bulky disease ≥5 cm, n (%)	69 (29)	73 (31)	44 (40)	
Cytopenia at baseline, n (%)d	102 (42)	110 (46)	61 (55)	
Unmutated <i>IGHV</i> , n/N (%)°	125/234 (53)	121/231 (52)	67/103 (65)	
del(11q), n (%)	43 (18)	46 (19)	37 (33)	
TP53 mutation, n/N (%)	15/232 (6)	13/223 (6)	47/109 (43)	
Complex karyotype with ≥3 abnormalities, n/N (%) ^f	23/164 (14)	22/161 (14)	33/88 (38)	


BR, bendamustine plus rituximab; CLL, chronic lymphocytic leukemia; ECOG PS, Eastern Cooperative Oncology Group performance status; IGHV, immunoglobulin heavy variable: SLL, small lymphocytic lymphoma. ^a One patient without del(17p) was misassigned to the nonrandomly assigned cohort of patients with del(17p). The patient is excluded from the efficacy analysis in this cohort; ^b Patients aged ≥75 years included 63 patients in group A (26%), 53 patients in group B (22%), and 27 patients in group C (24%); ^c Patients with SLL had Binet stage calculated as if they had CLL; ^d Defined as having anemia (hemoglobin ≤110 g/L), thrombocytopenia (platelets ≤100×10⁹/L), or neutropenia (absolute neutrophil count ≤1.5×10⁹/L); e Twenty-two patients had insufficient RNA quantity/quality for polymerase chain reaction amplification of IGHV region for sequencing or had missing data; f Patients with missing/insufficient metaphase activity were omitted from the complex karyotype analysis.


Efficacy


- In cohort 1, median PFS was not reached in patients who received zanubrutinib; in patients who received BR, median PFS was 42.2 months (Figure 2A)
 - Estimated 42-month PFS rates with zanubrutinib and BR were 82.4% and 50.0%, respectively
- PFS was significantly improved with zanubrutinib vs BR in patients with mutated IGHV (2-sided P=.00033) and unmutated IGHV (2-sided P<.0001) (**Figure 2B**)
- CR/CR with incomplete hematologic recovery (CRi) rates in patients without del(17p) who received zanubrutinib vs BR were 17.4% vs 21.8%, respectively
- Median OS was not reached in either group; the estimated 42-month OS rates were 89.4% and 88.3%, respectively (Figure 2C)
- In cohort 2, the median PFS and OS were not reached; the estimated 42-month rates were 79.4% and 89.5%, respectively (Figure 2D), and the CR/CRi rate was 14.5%


Figure 2. PFS and OS in Cohort 1 (Without del[17p]) and Cohort 2 (With del[17p])^a











BR, bendamustine plus rituximab; IGHV, immunoglobulin heavy variable; m, median; NE, not evaluable; zanu, zanubrutinib. ^a All P values are 2-sided and descriptive only

CONCLUSIONS

- The extended follow-up in the SEQUOIA study showed that the efficacy of zanubrutinib was maintained in previously untreated patients with CLL/SLL without del(17p) and that PFS rates were similar in patients with and without del(17p); OS rates were high in all arms of the trial
- Additionally, patients with mutated IGHV who received zanubrutinib demonstrated significant improvements in PFS with extended follow-up vs those who received BR; patients with unmutated *IGHV* who received zanubrutinib maintained the PFS benefit vs patients who received BR that was observed at the interim analysis
- Zanubrutinib was well tolerated over this extended treatment period and aligned with the known profile of BTK inhibitors; atrial fibrillation events remained low
- The results of this extended follow-up in the SEQUOIA study support the use of zanubrutinib as a valuable first-line treatment option for elderly patients with CLL/SLL and those with del(17p)

Safety

- AEs of interest (AEIs) in patients without del(17p) receiving zanubrutinib vs BR and in patients with del(17p) are shown in **Table 2**
- Exposure-adjusted incidence rates for hypertension were similar between arms and lower than previously reported (Table 3)

Table 2. Treatment-Emergent and Posttreatment AEIs^a in Cohorts 1 and 2 (Any Grade and Grade ≥3)^b

	Patients without del(17p)			Patients with del(17p)		
	Arm A: zar (n=2		Arm B: BR (n=227) ^b		Arm C: zanubrutinib (n=111)	
AEIs, n (%)	Any grade	Grade ≥3	Any grade	Grade ≥3	Any grade	Grade ≥3
Infections	175 (72.9)	57 (23.8)	142 (62.6)	50 (22.0)	89 (80.2)	30 (27.0)
Bleeding	117 (48.8)	14 (5.8)	28 (12.3)	4 (1.8)	64 (57.7)	6 (5.4)
Other malignancies	45 (18.8)	22 (9.2)	28 (12.3)	11 (4.8)	27 (24.3)	8 (7.2)
Hypertension	42 (17.5)	22 (9.2)	31 (13.7)	15 (6.6)	15 (13.5)	7 (6.3)
Diarrhea	41 (17.1)	4 (1.7)	32 (14.1)	5 (2.2)	22 (19.8)	1 (0.9)
Neutropenia	40 (16.7)	30 (12.5)	129 (56.8)	116 (51.1)	21 (18.9)	18 (16.2)
Arthralgia	37 (15.4)	2 (0.8)	23 (10.1)	1 (0.4)	26 (23.4)	1 (0.9)
Anemia	17 (7.1)	1 (0.4)	47 (20.7)	5 (2.2)	7 (6.3)	0 (0)
Thrombocytopenia	15 (6.3)	5 (2.1)	41 (18.1)	18 (7.9)	9 (8.1)	2 (1.8)
Atrial fibrillation/flutter	12 (5.0)	3 (1.3)	6 (2.6)	3 (1.3)	7 (6.3)	5 (4.5)
Myalgia	9 (3.8)	0 (0)	4 (1.8)	0 (0)	8 (7.2)	1 (0.9)
Opportunistic infection	6 (2.5)	1 (0.4)	4 (1.8)	3 (1.3)	1 (0.9)	1 (0.9)

AEI, AE of interest; BR, bendamustine plus rituximat a Patients who did not receive zanubrutinib are not included in the safety analysis; b Patients who did not receive BR are not included in the safety analysis

Table 3. Summary of EAIRs^a for Select AEIs

	Patients without del(Patients with del(17p)		
	Arm A: zanubrutinib (n=240) ^b	Arm B: BR (n=227)°	Arm C: zanubrutinib (n=111)	
Atrial fibrillation and flutter	0.13	0.08	0.15	
Hemorrhage	2.02	0.40	2.73	
Major hemorrhage	0.20	0.05	0.20	
Hypertension	0.49	0.45	0.35	

AEI, AE of interest; BR, bendamustine plus rituximab; EAIR, exposure-adjusted incidence rate. ^a EAIR was calculated as the number of patients with an event in each TEAE category divided by the total time from the first dose date to the first event date, or the exposure time if no event occurred: ^b Patients who did not receive zanubrutinib are not included in the safety analysis; ^c Patients who did not receive BR are not included in

REFERENCES 1. Scheffold A, Stilgenbauer S. Curr Oncol Rep. 2020;22(2):16.

2. Guo Y, et al. J Med Chem. 2019;62(17):7923-7940. 3. Brukinsa (zanubrutinib). Package insert. BeiGene USA; 2023. 4. Brukinsa (zanubrutinib). Summary of product characteristics.

5. BeiGene, BeiGene receives new approvals for BRUKINSA® (zanubrutinib) in China. Accessed May 22, 2023. https://ir.beigene.com/news/beigenereceives-new-approvals-for-brukinsa-zanubrutinib-in-china/7e5cd979-7835 4263-8dde-f426c721fb3e/ 6. Tam CS, et al. Lancet Oncol. 2022;23(8):1031-1043.

DISCLOSURES SO: Consulting fees: AbbVie, Antengene, AstraZeneca, BeiGene, BMS, CSL Behring, Gilead, Merck, Novartis, Janssen, Roche, Takeda; Research funding: AbbVie,

BeiGene Ireland Ltd: 2021

AstraZeneca, BeiGene, BMS, Gilead, Janssen, Merck, Novartis, Pharmacyclics, Roche, Takeda; Honoraria: AbbVie, AstraZeneca, BeiGene, BMS, Gilead, Janssen, Merck, Novartis, Pharmacyclics, Roche, Takeda; Honoraria: AbbVie, AstraZeneca, BeiGene, BMS, Gilead, Janssen, Merck, Novartis, Pharmacyclics, Roche, Takeda; Honoraria: AbbVie, AstraZeneca, BeiGene, BMS, Gilead, Janssen, Merck, Novartis, Pharmacyclics, Roche, Takeda; Honoraria: AbbVie, AstraZeneca, BeiGene, BMS, Gilead, Janssen, Merck, Novartis, Pharmacyclics, Roche, Takeda; Honoraria: AbbVie, AstraZeneca, BeiGene, BMS, Gilead, Janssen, Merck, Novartis, Pharmacyclics, Roche, Takeda; Honoraria: AbbVie, AstraZeneca, BeiGene, BMS, Gilead, Janssen, Merck, Novartis, Pharmacyclics, Roche, Takeda; Honoraria: AbbVie, AstraZeneca, BeiGene, BMS, Gilead, Janssen, Merck, Novartis, Pharmacyclics, Roche, Takeda; Honoraria: AbbVie, AstraZeneca, BeiGene, BMS, Gilead, Janssen, Merck, Martin, Mar Novartis, Roche, Takeda; Membership on an Entity's Board of Directors or Advisory Committees: AbbVie, AstraZeneca, BeiGene, BMS, Gilead, Janssen, Merck, Novartis, Roche, Takeda outside the submitted work. TM: Honoraria: Janssen, AbbVie, Gilead, Alexion, Novartis, Roche; Consulting role: MorphoSys, Sunesis. MS: Consulting fees: AbbVie, Genetech, AstraZeneca, Sound Biologics, Pharmacyclics, BeiGene, Bristol Myers Squibb, MorphoSys/Incyte, TG Therapeutics, Innate Pharma, Kite Pharma, Adaptive Biotechnologies, Epizyme, Eli Lilly, Adaptimmune, Mustang Bio, Regeneron, Merck, Fate Therapeutics, MEI Pharma, Atara Biotherapeutics: Research funding: Mustang Bio, Celgene, Bristol Myers Squibb, Pharmacyclics, Gilead, Genentech, AbbVie, TG Therapeutics, BeiGene, AstraZeneca, Sunesis, Atara Biotherapeutics, Genmab, MorphoSys/Incyte, Vincerx. TR: Research funding: BeiGene, Octapharma, AstraZeneca, Janssen, Regeneron, GSK; Honoraria: AstraZeneca, BeiGene, Janssen, AbbVie, Octapharma, Regeneron, GSK; Travel, accommodations, expenses: AstraZeneca. JRB: Consulting fees: AbbVie, Acerta/AstraZeneca, BeiGene, Bristol Myers Squibb/Juno/Celgene, Catapult, Eli Lilly, Genentech/Roche, Grifols Worldwide Operations, Hutchmed, iOnctura, Janssen, MEI Pharma, Pfizer, Pharmacyclics; Research funding: BeiGene, Gilead, iOnctura, Loxo/Lilly, MEI Pharma, SecuraBio, Sun, TG Therapeutics. BSK: Research funding: BeiGene to Washington University School of Medicine (St Louis, MO, USA); Consulting fees: AbbVie, AstraZeneca, BeiGene, Janssen, Pharmacyclics. PG: Honoraria: AbbVie, ArQule/MSD, AstraZeneca, BeiGene, Celgene/Juno/BMS, Janssen, Lilly/Loxo, MEI, Roche, Sanofi; Research funding: AbbVie, AstraZeneca, Janssen, Sunesis. KG: Consulting fees: BeiGene; Funding: AbbVie, Amgen, AstraZeneca, Janssen, Novartis, Roche, Sanofi-Genzyme, Takeda, and paid to the Next Generation Hematology Association; Consulting fees: GSK, Sandoz; Honoraria: AbbVie, Amgen, AstraZeneca, BeiGene, Gilead, GSK, Janssen, Karyopharm, Novartis, Pfizer, Roche, Sandoz, Takeda, Teva; Travel, accommodations, expenses Janssen, Roche, Sanofi-Genzyme; Advisory board: AbbVie, Amgen, AstraZeneca, Gilead, GSK, Janssen, Novartis, Roche, Sandoz, Takeda; Leadership role: the Next Generation Hematology Association. MS: Consulting fees: AbbVie, AstraZeneca, Janssen-Cilag; Individual stocks: AbbVie, AstraZeneca, Johnson & Johnson, BeiGene, Gilead, Baxter, Novartis, Abbot, Sanofi; Honoraria: AbbVie, Janssen-Cilag, AstraZeneca; Membership on an Entity's Board of Directors or Advisory Committees: AbbVie, Janssen-Cilag, AstraZeneca; Travel, accommodations, expenses: AbbVie, Janssen-Cilag, AstraZeneca. RG: Consulting fees: AbbVie, AstraZeneca, Bristol Myers Squibb, Celgene, Daiichi Sankyo, Gilead, Janssen, Merck, MSD, Novartis, Roche, Takeda; Honoraria: AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Celgene, Daiichi Sankyo, Gilead, Merck, MSD, Novartis, Roche, Takeda, Sandoz; Financial support for attending meetings or travel, or both: AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Celgene, Daiichi Sankyo, Gilead, Janssen, MSD, Novartis, Roche; Advisory board: AbbVie, AstraZeneca, Bristol Myers Squibb, Celgene, Daiichi Sankyo, Gilead, Janssen, Merck, MSD, Novartis, Roche, Takeda outside the submitted work. MTr: Consulting fees: AbbVie, Amgen, Janssen, Bristol Myers Squibb, Gilead Sciences, Incyte, MorphoSys, Novartis, Roche, Takeda; Honoraria: AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Gilead Sciences, Incyte, Janssen, Roche, MorphoSys, Novartis, Portolla, Takeda; Financial support for attending meetings or travel, or both: AbbVie, Bristol Myers Squibb, Gilead, Janssen, Roche, Takeda; Advisory board: AbbVie, Bristol Myers Squibb, Incyte, Janssen, MorphoSys, Novartis, Portolla, Roche, Takeda; Employment at Charles University General Hospital in Prague, outside the submitted work. **DMB:** Funding from AbbVie, ArQule, Ascentage, AstraZeneca, BeiGene, DTRM, Genentech, Juno–Celgene–Bristol Myers Squibb, LOXO, MEI Pharma, Novartis, Pharmacyclics, TG Therapeutics; Consulting fees: AbbVie, Genentech, Pharmacyclics, Pfizer, TG Therapeutics, Verastem; Advisory board: AbbVie, Genentech, Novartis, Pharmacyclics, Pfizer, TG Therapeutics, Verastem; Leadership role with NCCN (panel member), informCLL registry (steering committee; AbbVie), and biosimilars outcomes research panel (Pfizer), outside the submitted work. IWF: Consultancy: (all payments made to Sarah Cannon Research Institute, not to the physician) AbbVie, AstraZeneca, BeiGene, Century Therapeutics, Genentech, Genmab, Hutchison MediPharma, Iksuda Therapeutics, InnoCare Pharma, Janssen, Kite Pharma, MorphoSys, Myeloid Therapeutics, Novartis, Nurix, Pfizer, Pharmacyclics, Portola Pharmaceuticals, Rhizen Pharmaceuticals, Roche, Seattle Genetics, Tessa Therapeutics, TCR2 Therapeutics, TG Therapeutics, Trillium Therapeutics, Triphase Research & Development Corp., Unum Therapeutics, Verastem, 2seventy bio; Membership on an Entity's Board of Directors or Advisory Committees: Vincerx. SG: No disclosures. EV: Research funding: Janssen Cilag Pty Ltd. AT: Consultancy: BeiGene, AstraZeneca, AbbVie, Janssen; Honoraria: BeiGene, AstraZeneca, AbbVie, Janssen; Speakers Bureau: BeiGene, AstraZeneca, AbbVie, Janssen; Travel, accommodations, expenses: BeiGene, AstraZeneca, AbbVie, Janssen. SD: Honoraria: Gilead Sciences, AbbVie, Janssen; Consultancy or advisory role: Gilead Sciences, AbbVie, Janssen. GT: No disclosures. KL: Grants/research support: AbbVie, Novartis, Takeda, Roche, Sandoz; Honoraria or speaker's bureau/personal fees: AbbVie, Novartis, Takeda, Roche, Sandoz, Celgene, Jansen, Amgen. JG: No disclosures. JL: No disclosures. TT: Employment: BeiGene. VR: Employment: BeiGene USA; Equity holder: BeiGene USA; Divested equity: BeiGene USA; Travel, accommodations, expenses: BeiGene USA. YL: Employment: BeiGene Ltd; Equity Holder: BeiGene Ltd; Travel, accommodations, expenses: BeiGene Ltd. AS: Employment: BeiGene. JP: Employment: BeiGene. AC: Employment: BeiGene; Equity holder: BeiGene; Travel, accommodations, expenses: BeiGene. CT: Research funding: Janssen, AbbVie, BeiGene; Honoraria: Janssen, AbbVie, BeiGene, Loxo, AstraZeneca, WJ: Consultancy: Janssen, AstraZeneca, Mei Pharma, Lilly, Takeda, Roche, AbbVie, BeiGene; Research funding: AbbVie, Bayer, BeiGene, Celgene, Janssen, Roche, Takeda, TG Therapeutics, AstraZeneca, Mei Pharma, Lilly.

ACKNOWLEDGMENTS

The authors thank the patients and their families, investigators, co-investigators, and the study teams at each of the participating centers. They also wish to recognize Carol Marimpietri, RN, Axel Gayko, Emily Mantovani, PharmD, Maria Salaverri, and Hany Hanalla, all from BeiGene, for their contributions to data analysis and operational support. This study was sponsored by BeiGene, Ltd. Medical writing support was provided by Shivani Naidoo, PhD, and Heather Taft, PhD (Medical Expressions, LLC), and was supported by BeiGene, Ltd.

